AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19922752 — intervention group
Group type: EXPERIMENTAL
Intervention: P300 amplitude
Number of subjects: 66
Study 17358101 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole 20mg on-demand treatment
Number of subjects: 199
Study 17358101 — intervention group
Group type: COMPARATOR
Intervention: Esomeprazole 20mg on-demand treatment
Number of subjects: 199
Study 16326371 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (200 mg)
Number of subjects: 42
Study 16326371 — intervention group
Group type: COMPARATOR
Intervention: Diphenhydramine (40 mg)
Number of subjects: 42
Study 11940697 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxandrolone
Number of subjects: 19
Study 11940697 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 9468416 — intervention group
Group type: EXPERIMENTAL
Intervention: 11.5F polyethylene stent to be exchanged in case of dysfunction (group 1, n = 33)
Number of subjects: 101
Study 9468416 — intervention group
Group type: EXPERIMENTAL
Intervention: 11.5F stent to be exchanged every 3 months (group 2, n = 34)
Number of subjects: 101
Study 9468416 — intervention group
Group type: EXPERIMENTAL
Intervention: Self‐expanding metallic Wallstent (group 3, n = 34)
Number of subjects: 101
Study 8552685 — intervention group
Group type: EXPERIMENTAL
Intervention: Formal asthma education programme delivered by an asthma nurse specialist
Number of subjects: 0
Study 8552685 — intervention group
Group type: COMPARATOR
Intervention: Standard information and education given to patients in a respiratory clinic
Number of subjects: 0
Study 2137435 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide 0.040 mg
Number of subjects: 10
Study 2137435 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide 0.200 mg
Number of subjects: 10
Study 6988949 — intervention group
Group type: EXPERIMENTAL
Intervention: Single preoperative dose of tinidazole 2 g and doxycycline 200 mg (n = 70)
Number of subjects: 265
Study 6988949 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline alone
Number of subjects: 265
Study 6988949 — intervention group
Group type: COMPARATOR
Intervention: Tinidazole alone
Number of subjects: 265
Study 6988949 — intervention group
Group type: COMPARATOR
Intervention: Two different combinations of the two antimicrobials
Number of subjects: 265
Study 30463637 — intervention group
Group type: EXPERIMENTAL
Intervention: B'More Healthy Communities for Kids (BHCK) intervention
Number of subjects: 516
Study 28114182 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted guideline implementation strategy
Number of subjects: 0
Study 28114182 — intervention group
Group type: COMPARATOR
Intervention: Usual implementation strategy
Number of subjects: 0
Study 25616223 — intervention group
Group type: EXPERIMENTAL
Intervention: Coarse CAP (2.5‐10 μm; mean, 213 μg/m3)
Number of subjects: 50
Study 25616223 — intervention group
Group type: EXPERIMENTAL
Intervention: Fine CAP (0.15‐2.5 μm; mean, 238 μg/m3)
Number of subjects: 50
Study 25616223 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrafine CAP (< 0.3 μm; mean, 136 μg/m3)
Number of subjects: 50
Study 25616223 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotoxin
Number of subjects: 50
Study 25616223 — intervention group
Group type: COMPARATOR
Intervention: Filtered ambient and/or medical air
Number of subjects: 50
Study 23356556 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg
Number of subjects: 78
Study 23356556 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg
Number of subjects: 78
Study 23356556 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 100 mg
Number of subjects: 78
Study 23356556 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 23356556 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin (all doses combined)
Number of subjects: 78
Study 21221770 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin 10.8 mg every 3 months
Number of subjects: 170
Study 21221770 — intervention group
Group type: COMPARATOR
Intervention: Goserelin 3.6 mg every month
Number of subjects: 170
Study 19114225 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Bone Setting (TBS)
Number of subjects: 131
Study 19114225 — intervention group
Group type: COMPARATOR
Intervention: Conventional Physical Therapy (PhT)
Number of subjects: 131
Study 16452640 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase concentration in the alpha frequency range
Number of subjects: 0
Study 16452640 — intervention group
Group type: EXPERIMENTAL
Intervention: Ongoing alpha activity prior to stimulus onset
Number of subjects: 0
Study 16452640 — intervention group
Group type: EXPERIMENTAL
Intervention: Evoked alpha oscillation in the ERP
Number of subjects: 0
Study 16452640 — intervention group
Group type: EXPERIMENTAL
Intervention: Lack of power increase during phase concentration
Number of subjects: 0
Study 16452640 — intervention group
Group type: EXPERIMENTAL
Intervention: Decrease in amplitude variance during early evoked components
Number of subjects: 0
Study 16452640 — intervention group
Group type: EXPERIMENTAL
Intervention: Same cortical sources for induced prestimulus power and evoked poststimulus power
Number of subjects: 0
Study 16452640 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation approach to test the additivity of the evoked response
Number of subjects: 0
Study 15064618 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway
Number of subjects: 74
Study 15064618 — intervention group
Group type: COMPARATOR
Intervention: Endotracheal tube
Number of subjects: 74
Study 11236773 — intervention group
Group type: EXPERIMENTAL
Intervention: Drotrecogin alfa activated (24 microg/kg/hour for 96 hours)
Number of subjects: 1690
Study 11236773 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1690
Study 11236773 — intervention group
Group type: EXPERIMENTAL
Intervention: Drotrecogin alfa activated
Number of subjects: 1690
Study 9778009 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 microg intrathecal neostigmine
Number of subjects: 92
Study 9778009 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 microg intrathecal neostigmine
Number of subjects: 92
Study 9778009 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 microg intrathecal neostigmine
Number of subjects: 92
Study 9778009 — intervention group
Group type: COMPARATOR
Intervention: saline placebo
Number of subjects: 92
Study 7923204 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (50 mg twice daily)
Number of subjects: 135
Study 7923204 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone (10 mg twice daily)
Number of subjects: 135
Study 7923204 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 135
Study 3289523 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam (mean dose, 4.2 mg/d)
Number of subjects: 55
Study 3289523 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (mean dose, 40.4 mg/d)
Number of subjects: 55
Study 3289523 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 31425468 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose ketamine (LDK) at 2 μg·kg·min
Number of subjects: 59
Study 31425468 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose ketamine (LDK)
Number of subjects: 59
Study 31425468 — intervention group
Group type: COMPARATOR
Intervention: 0.9% normal saline (control)
Number of subjects: 59
Study 28936678 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarker-based strategy (using (1,3)-β-D-glucan, mannan, and anti-mannan serum assays)
Number of subjects: 110
Study 28936678 — intervention group
Group type: COMPARATOR
Intervention: Routine care strategy (based on international guidelines recommending 14 days of treatment)
Number of subjects: 110
Study 28936678 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarker-based strategy
Number of subjects: 110
Study 28936678 — intervention group
Group type: COMPARATOR
Intervention: Routine care strategy
Number of subjects: 110
Study 25527447 — intervention group
Group type: EXPERIMENTAL
Intervention: FAST (rapid identification and antibiotic susceptibility testing using PCR)
Number of subjects: 250
Study 25527447 — intervention group
Group type: COMPARATOR
Intervention: SOC (standard of care testing using the BD Phoenix system)
Number of subjects: 250
Study 24048857 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg d-amphetamine orally
Number of subjects: 24
Study 24048857 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 21137035 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flux hemodialysis treatment
Number of subjects: 16
Study 21137035 — intervention group
Group type: COMPARATOR
Intervention: Low-flux hemodialysis treatment
Number of subjects: 16
Study 21137035 — intervention group
Group type: COMPARATOR
Intervention: Control sets (post-dialytic samples from patients and samples from healthy controls)
Number of subjects: 16
Study 21137035 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flux and low-flux hemodialysis treatments
Number of subjects: 16
Study 19036450 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional services plus the services of a recovery coach (experimental group)
Number of subjects: 931
Study 19036450 — intervention group
Group type: COMPARATOR
Intervention: Traditional services (control group)
Number of subjects: 931
Study 19036450 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery coaches (experimental group)
Number of subjects: 931
Study 16877894 — intervention group
Group type: EXPERIMENTAL
Intervention: Kava
Number of subjects: 64
Study 16877894 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 16877894 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 64
Study 14692708 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (400 IU daily for 10 weeks)
Number of subjects: 20
Study 14692708 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 14692708 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E
Number of subjects: 20
Study 10824629 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intravenous infusion of rTFPI (0.2 mg/kg/h) with intravenous sorbitol (50 mg/min) for 4 hours during exercise
Number of subjects: 8
Study 10824629 — intervention group
Group type: COMPARATOR
Intervention: Continuous intravenous infusion of rTFPI (0.2 mg/kg/h) with intravenous sorbitol (50 mg/min) for 4 hours in supine position
Number of subjects: 8
Study 8641622 — intervention group
Group type: EXPERIMENTAL
Intervention: ip mitoxantrone 10 mg/m2 every 2 weeks X 9
Number of subjects: 67
Study 8641622 — intervention group
Group type: EXPERIMENTAL
Intervention: ip floxuridine (FUDR) 3 g (total dose)/ day X 3 days every 3 weeks X 6 cycles
Number of subjects: 67
Study 1735812 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP-CRM (polyribosylribitol phosphate conjugated with mutant diphtheria protein)
Number of subjects: 0
Study 1735812 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP-T (polyribosylribitol phosphate conjugated with tetanus toxoid)
Number of subjects: 0
Study 1735812 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP-OMP (polyribosylribitol phosphate conjugated with outer-membrane protein of Neisseria meningitidis)
Number of subjects: 0
Study 1735812 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP-D (polyribosylribitol phosphate conjugated with diphtheria toxoid)
Number of subjects: 0
Study 1735812 — intervention group
Group type: COMPARATOR
Intervention: Conventional diphtheria-tetanus-pertussis vaccine
Number of subjects: 0
Study 6405430 — intervention group
Group type: EXPERIMENTAL
Intervention: Apomorphine
Number of subjects: 8
Study 6405430 — intervention group
Group type: COMPARATOR
Intervention: Promazine
Number of subjects: 8
Study 6405430 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 30445177 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense pulsed light (IPL) combined with meibomian gland expression (MGX)
Number of subjects: 45
Study 30445177 — intervention group
Group type: COMPARATOR
Intervention: Meibomian gland expression (MGX) alone
Number of subjects: 45
Study 29453383 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBOT) + steroids
Number of subjects: 18
Study 29453383 — intervention group
Group type: COMPARATOR
Intervention: Sham hyperbaric air + steroids
Number of subjects: 18
Study 26890171 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight Watchers weight‐management program (n=112)
Number of subjects: 225
Study 26890171 — intervention group
Group type: COMPARATOR
Intervention: Your Game Plan to Prevent Type 2 Diabetes (Control)
Number of subjects: 225
Study 24494737 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral sacroiliac joint manipulation and mobilization without tension of the hips in supine position
Number of subjects: 62
Study 24494737 — intervention group
Group type: COMPARATOR
Intervention: Mobilization without tension of the hips in supine position
Number of subjects: 62
Study 22677023 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular ozone gas injection (2 mL ozone-oxygen mixture, ozone gas concentration 10 μg/mL, injected 2 times per week for 3 weeks)
Number of subjects: 60
Study 22677023 — intervention group
Group type: COMPARATOR
Intervention: Nonsteroidal antiinflammatory drugs and muscle relaxants
Number of subjects: 60
Study 20509987 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Treatment (CBT) for anxiety disorders
Number of subjects: 99
Study 17828004 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive-educative approach
Number of subjects: 88
Study 17828004 — intervention group
Group type: EXPERIMENTAL
Intervention: Mutual goal-setting approach
Number of subjects: 88
Study 17828004 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 88
Study 16052246 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (200 mg daily) plus oxcarbazepine (600 mg twice daily)
Number of subjects: 47
Study 16052246 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (200 mg daily) plus placebo
Number of subjects: 47
Study 16052246 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxcarbazepine (600 mg twice daily) plus placebo
Number of subjects: 47
Study 16052246 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 12369475 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy (DBT)
Number of subjects: 58
Study 12369475 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 58
Study 9987807 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (NLTX)
Number of subjects: 2
Study 7780494 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexfenfluramine (15 mg twice daily)
Number of subjects: 60
Study 7780494 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 2175265 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg delta‐9‐tetrahydrocannabinol (THC) p.o.
Number of subjects: 1
Study 2175265 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg codeine p.o.
Number of subjects: 1
Study 2175265 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1
Study 7002181 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxyfedrine (24 mg three times daily)
Number of subjects: 23
Study 7002181 — intervention group
Group type: COMPARATOR
Intervention: Isosorbide dinitrate (10 mg three times daily)
Number of subjects: 23
Study 7002181 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 29712500 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (continuous infusion of fentanyl)
Number of subjects: 53
Study 29712500 — intervention group
Group type: COMPARATOR
Intervention: Control (continuous infusion of glucose)
Number of subjects: 53
Study 28341683 — intervention group
Group type: EXPERIMENTAL
Intervention: Black tea intake (cups per day)
Number of subjects: 1055
Study 28341683 — intervention group
Group type: EXPERIMENTAL
Intervention: Total fluid intake (cups per day)
Number of subjects: 1055
Study 28341683 — intervention group
Group type: EXPERIMENTAL
Intervention: Water intake (cups per day)
Number of subjects: 1055
Study 28341683 — intervention group
Group type: EXPERIMENTAL
Intervention: Other fluids intake (cups per day)
Number of subjects: 1055
Study 26012124 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonic J-pouch anastomosis
Number of subjects: 80
Study 26012124 — intervention group
Group type: COMPARATOR
Intervention: Latero-terminal anastomosis
Number of subjects: 80
Study 23895258 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated treatment for alcohol and social phobia (9 sessions)
Number of subjects: 0
Study 23895258 — intervention group
Group type: COMPARATOR
Intervention: Treatment for alcohol use problems alone (9 sessions)
Number of subjects: 0
Study 21823550 — intervention group
Group type: EXPERIMENTAL
Intervention: Remoxy (extended-release oxycodone) 5 mg bid to 20 mg bid, titrated during weeks 1-4 (10-80 mg/d) and fixed thereafter for 12 weeks
Number of subjects: 558
Study 21823550 — intervention group
Group type: EXPERIMENTAL
Intervention: Remoxy
Number of subjects: 558
Study 21823550 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 558
Study 18371962 — intervention group
Group type: EXPERIMENTAL
Intervention: Monopolar electrodes using glycine 1.5% as irrigant
Number of subjects: 200
Study 18371962 — intervention group
Group type: EXPERIMENTAL
Intervention: TCRis bipolar electrodes using saline as irrigant
Number of subjects: 200
Study 18371962 — intervention group
Group type: COMPARATOR
Intervention: Versapoint bipolar electrodes using saline as irrigant
Number of subjects: 200
Study 18371962 — intervention group
Group type: COMPARATOR
Intervention: Bipolar electrodes (TCRis and Versapoint)
Number of subjects: 200
Study 17066515 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTA)
Number of subjects: 52
Study 17066515 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTA) + alpha-adrenergic antagonist
Number of subjects: 52
Study 12848902 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemostatic gene polymorphisms (beta-fibrinogen and platelet glycoprotein Ia, Ib, and IIb/IIIa)
Number of subjects: 0
Study 12848902 — intervention group
Group type: COMPARATOR
Intervention: Sex- and age-matched controls
Number of subjects: 0
Study 11139093 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass graft surgery (CABG)
Number of subjects: 0
Study 11139093 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous transluminal coronary angioplasty (PTCA)
Number of subjects: 0
Study 11139093 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass graft surgery (CABG) with internal mammary artery (IMA) graft
Number of subjects: 0
Study 9377884 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine
Number of subjects: 36
Study 9377884 — intervention group
Group type: COMPARATOR
Intervention: Norepinephrine
Number of subjects: 36
Study 8442747 — intervention group
Group type: EXPERIMENTAL
Intervention: Thought suppression with distraction instructions
Number of subjects: 0
Study 8442747 — intervention group
Group type: COMPARATOR
Intervention: Thought suppression without distraction instructions
Number of subjects: 0
Study 3676185 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg supplementary vitamin E/d
Number of subjects: 42
Study 3676185 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg supplementary vitamin E/d
Number of subjects: 42
Study 3676185 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 31307844 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep-study guided multidisciplinary therapy (SGMT)
Number of subjects: 159
Study 31307844 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 159
Study 29218448 — intervention group
Group type: EXPERIMENTAL
Intervention: Spa treatment including thermal water baths, physical therapy modalities, and exercises
Number of subjects: 80
Study 29218448 — intervention group
Group type: COMPARATOR
Intervention: Home exercises for 15 days
Number of subjects: 80
Study 29218448 — intervention group
Group type: EXPERIMENTAL
Intervention: Spa treatment
Number of subjects: 80
Study 26929878 — intervention group
Group type: EXPERIMENTAL
Intervention: Third trimester ultrasonographic exams (USE)
Number of subjects: 50
Study 26929878 — intervention group
Group type: COMPARATOR
Intervention: Routine prenatal care (RPNC)
Number of subjects: 50
Study 24782426 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutamide (a selective non-steroidal AR antagonist)
Number of subjects: 19
Study 24782426 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 23321191 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial axillary node dissection
Number of subjects: 1127
Study 23321191 — intervention group
Group type: COMPARATOR
Intervention: Conventional dissection
Number of subjects: 1127
Study 19888994 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue Doppler Imaging (TDI)
Number of subjects: 32
Study 19888994 — intervention group
Group type: COMPARATOR
Intervention: Control (healthy children)
Number of subjects: 32
Study 17689737 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct coronary artery stenting with drug eluting stents
Number of subjects: 68
Study 17689737 — intervention group
Group type: COMPARATOR
Intervention: Stenting after balloon predilatation
Number of subjects: 68
Study 16840657 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIL-6 infusion (5 microg/h for 3 h)
Number of subjects: 12
Study 16840657 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIL-6 infusion
Number of subjects: 12
Study 16840657 — intervention group
Group type: COMPARATOR
Intervention: albumin infusion (control)
Number of subjects: 12
Study 15087636 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural ropivacaine
Number of subjects: 14
Study 15087636 — intervention group
Group type: COMPARATOR
Intervention: Epidural morphine
Number of subjects: 14
Study 11297480 — intervention group
Group type: EXPERIMENTAL
Intervention: LASIK for myopia (n=35, -1.00 to -15.50 D, mean -4.75 +/- -3.07 D)
Number of subjects: 57
Study 11297480 — intervention group
Group type: EXPERIMENTAL
Intervention: LASIK for myopic astigmatism (n=22, sphere 0.00 to -9.75 D, mean -4.75 +/- 2.36 D; cylinder -0.75 to -3.50 D, mean -1.68 +/- 0.86 D)
Number of subjects: 57
Study 11297480 — intervention group
Group type: EXPERIMENTAL
Intervention: LASIK with RBT <= 250 microm
Number of subjects: 57
Study 11297480 — intervention group
Group type: EXPERIMENTAL
Intervention: LASIK
Number of subjects: 57